Molbio Diagnostics Raises ₹281.5 Cr Anchor Round for IPO
By ThePip Desk
Molbio Diagnostics secures ₹281.5 crore anchor investment from global giants like Goldman Sachs and BlackRock ahead of its ₹940 crore IPO.
Molbio Diagnostics successfully secured ₹281.5 crore from anchor investors. This crucial funding round takes place ahead of its larger ₹940 crore Initial Public Offering (IPO).
Key Anchor Investor Participation
Notable global and domestic institutions participated in this anchor allocation. These included major players from the financial sector.
- Goldman Sachs
- BlackRock
- HDFC Mutual Fund
- International Finance Corporation (IFC)
The IFC’s investment, totaling ₹20 crore, marks a significant return. It is the World Bank Group’s private-sector investment arm’s first foray into India’s mainboard IPO market in five years. Their last participation was with Dodla Dairy in June 2021.
Anchor Share Distribution
The anchor allocation involved a substantial distribution of equity shares. A total of 34.87 lakh shares were spread across numerous investors.
- 34.87 lakh equity shares distributed
- 33 distinct investors participated
- Price per share was set at ₹807, the upper end of the IPO’s price band (₹768-807)
- Domestic mutual funds received the largest portion, securing 67.51% of the allocated shares
The main IPO opens today and is scheduled to close on August 12. It comprises both a fresh issue and an Offer For Sale component.
IPO Structure and Funding Utilisation
The offering is structured to raise capital for specific strategic initiatives. Funds from the fresh issue are designated for operational expansion.
- Fresh issue component: ₹200 crore
- Offer For Sale (OFS) component: ₹739.7 crore
Proceeds from the fresh issue are primarily aimed at capital expenditure. This includes establishing an R&D facility and a Centre of Excellence. Additionally, funds will cover purchasing equipment for its Goa and Visakhapatnam units.
Several brokerages, including SBI Securities and Swastika Investmart, have recommended subscribing to the IPO. They cited Molbio’s strong growth prospects in molecular diagnostics, its scalable business model, and reasonable valuation compared to industry peers.